Contents

Issue 102 • January 2021

In association with

Pharma in the age of Biden

With President-elect Joe Biden set to take office in January, how will his administration approach the pharma industry?

IN DEPTH

Brexit: preventing counterfeit drugs

Comment

IDMP: What lies ahead?

Briefing

Industry news

Pharma industry briefing

Covid-19 briefing

Comment

Pipeline agents in the RA market

The rising role of the microbiome in R&D

IMDP: the benefit of hindsight

In Depth

Solving the puzzle of Hepatitis C

Is self-medication the future of pharma?

How do you fast-track a vaccine?

Healthcare’s sustainability goals

New Zealand: a promising trial destination

In Data

Inside the deal

Deals analysis

Market data

12/17/2020 15:06:39
  • Home | Is Joe Biden good news for US pharma?
  • In this issue
  • Contents
  • Mimotopes
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • HOF Sonderanlagenbau Company Insight
  • HOF Sonderanlagenbau
  • Comment
  • Pipeline agents in the RA market
  • US seeing alarming increases in Covid-19 cases
  • IDMP: Where are we now and what lies ahead?
  • The rising role of the microbiome
  • What the pandemic highlights about IDMP’s potential
  • In Depth
  • Solving the puzzle of Hepatitis C
  • Why is President-elect Joe Biden a good pick for the pharma industry?
  • Is self-medication the future of pharma?
  • Restricted growth: Challenging attitudes to achondroplasia
  • How do you fast-track a vaccine? UCL scientists weigh in
  • Fraudulent pharmaceuticals: the legacy of anti-counterfeit packaging
  • Are healthcare’s sustainability goals bold enough?
  • New Zealand: a promising destination for trials in a post-Covid-19 world?
  • In Data
  • Inside the deal
  • Deals analysis
  • The pharma industry key list
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Events
  • Next issue